M
Midory Thorikay
Researcher at Leiden University Medical Center
Publications - 14
Citations - 1501
Midory Thorikay is an academic researcher from Leiden University Medical Center. The author has contributed to research in topics: Angiogenesis & Transforming growth factor. The author has an hindex of 9, co-authored 13 publications receiving 1351 citations. Previous affiliations of Midory Thorikay include Netherlands Cancer Institute.
Papers
More filters
Journal ArticleDOI
Endoglin promotes endothelial cell proliferation and TGF‐β/ALK1 signal transduction
Franck Lebrin,Marie-José Goumans,Marie-José Goumans,Leon Jonker,Rita L. C. Carvalho,Gudrun Valdimarsdottir,Midory Thorikay,Christine L. Mummery,Helen M. Arthur,Peter ten Dijke +9 more
TL;DR: The results indicate a pivotal role for endoglin in the balance of ALK1 and ALK5 signalling to regulate endothelial cell proliferation and blocks TGF‐β‐induced growth arrest by indirectly reducing T GF‐β/ALK5 signalling.
Journal ArticleDOI
Elucidation of Smad Requirement in Transforming Growth Factor-β Type I Receptor-induced Responses
Susumu Itoh,Midory Thorikay,Marcin Kowanetz,Aristidis Moustakas,Fumiko Itoh,Carl-Henrik Heldin,Peter ten Dijke +6 more
TL;DR: Mutation in the L45 loop region did not affect the binding of inhibitory Smads but did abrogate the weak binding of X-linked inhibitor of apoptosis protein and Disabled-2 to ALK5, which suggests that the L 45 loop in the kinase domain is important for docking of other binding proteins.
Journal ArticleDOI
Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis
Sara I. Cunha,Evangelia Pardali,Midory Thorikay,Charlotte Anderberg,Lukas J. A. C. Hawinkels,Marie-José Goumans,Jasbir Seehra,Carl-Henrik Heldin,Peter ten Dijke,Kristian Pietras +9 more
TL;DR: It is demonstrated, by genetic and pharmacological means, that the TGF-β and BMP9 receptor activin receptor-like kinase (ALK) 1 represents a new therapeutic target for tumor angiogenesis and offers mechanistic insight for the forthcoming clinical development of drugs blocking ALK1 in oncology.
Journal ArticleDOI
ALK1 Opposes ALK5/Smad3 Signaling and Expression of Extracellular Matrix Components in Human Chondrocytes†
TL;DR: This work examined ALK1 expression and its regulation of TGF‐β signaling and responses in human chondrocytes and identified ALK2 as a second type I T GF‐β receptor.
Journal ArticleDOI
Anti-human Activin Receptor-like Kinase 1 (ALK1) Antibody Attenuates Bone Morphogenetic Protein 9 (BMP9)-induced ALK1 Signaling and Interferes with Endothelial Cell Sprouting
Laurens A. van Meeteren,Midory Thorikay,Simon Bergqvist,Evangelia Pardali,Corrado Gallo Stampino,Dana D. Hu-Lowe,Marie-José Goumans,Peter ten Dijke +7 more
TL;DR: The data suggest that both the VEGF/VEGF receptor and the BMP9/ALK1 pathways are essential for stimulating angiogenesis, and targeting both pathways simultaneously may be an attractive strategy to overcome resistance to antiangiogenesis therapy.